Circulating biomarkers to monitor cancer progression and treatment
Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of s...
Главные авторы: | Suthee Rapisuwon, Eveline E. Vietsch, Anton Wellstein |
---|---|
Формат: | Статья |
Язык: | English |
Опубликовано: |
Elsevier
2016-01-01
|
Серии: | Computational and Structural Biotechnology Journal |
Предметы: | |
Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2001037016300113 |
Схожие документы
-
Circulating cell-free nucleic acids of plasma in human aging, healthy aging and longevity: current state of knowledge
по: Nicolas P. Tessier, и др.
Опубликовано: (2023-11-01) -
Circulating Cell-free Tumor Nucleic Acids in Gastric Cancer
по: Hyun-Ji Lee, и др.
Опубликовано: (2018-09-01) -
The Role of Circulating Biomarkers in Lung Cancer
по: Sayuri Herath, и др.
Опубликовано: (2022-01-01) -
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective
по: Sridhar Mishra, и др.
Опубликовано: (2024-12-01) -
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
по: Pablo J. Dopico, и др.
Опубликовано: (2022-03-01)